AngioDynamics (NASDAQ:ANGO) Releases FY 2025 Earnings Guidance

AngioDynamics (NASDAQ:ANGO) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided earnings per share guidance of -0.380–0.340 for the period, compared to the consensus earnings per share estimate of -0.400. The company issued revenue guidance of $282.0 million-$288.0 million, compared to the consensus revenue estimate of $283.9 million. AngioDynamics also updated its FY25 guidance to ($0.38)-($0.34) EPS.

AngioDynamics Price Performance

AngioDynamics stock opened at $12.94 on Friday. The firm’s fifty day moving average price is $8.12 and its 200 day moving average price is $7.38. The company has a market capitalization of $525.80 million, a price-to-earnings ratio of -2.12 and a beta of 0.59. AngioDynamics has a 12-month low of $5.26 and a 12-month high of $13.13.

AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings results on Wednesday, January 8th. The medical instruments supplier reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.07. The business had revenue of $72.90 million during the quarter, compared to analyst estimates of $70.93 million. AngioDynamics had a negative net margin of 83.95% and a negative return on equity of 5.86%. The business’s revenue was down .1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.05) earnings per share. Analysts forecast that AngioDynamics will post -0.41 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ANGO has been the topic of several research reports. Canaccord Genuity Group dropped their price objective on shares of AngioDynamics from $13.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday, October 4th. HC Wainwright reissued a “buy” rating and set a $14.00 price target on shares of AngioDynamics in a report on Tuesday, December 10th.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.